[奈达铂与依托泊苷联合化疗用于一名接受血液透析的小细胞癌患者]
[Nedaplatin and etoposide combination chemotherapy in a patient with small cell carcinoma undergoing hemodialysis].
作者信息
Nishioka Y, Kitada O, Meguro T, Aragane K, Tanimukai T, Nakamura H, Nakahama H, Matsuyama T, Sugita M, Yano T, Takenaka Y, Takamitsu Y
机构信息
5th Dept. of Internal Medicine, Hyogo College of Medicine.
出版信息
Gan To Kagaku Ryoho. 1999 Mar;26(4):527-30.
A 61-year-old man with chronic renal failure caused by polycystic kidney disease requiring hemodialysis three times weekly developed small cell carcinoma of the lung. The patient received combination chemotherapy with nedaplatin (50 mg) and etoposide (50 mg). Blood levels were monitored, showing that nedaplatin was more dialyzable than cisplatin. The patient achieved a complete response. These results suggest that nedaplatin-etoposide combination chemotherapy may be safer than cisplatin-containing regimen for patients with chronic renal failure hemodialysis and that a satisfactory response can be expected.
一名61岁因多囊肾导致慢性肾衰竭且每周需进行三次血液透析的男性患者罹患了小细胞肺癌。该患者接受了奈达铂（50毫克）和依托泊苷（50毫克）的联合化疗。对血液水平进行监测后发现，奈达铂比顺铂更容易被透析清除。该患者实现了完全缓解。这些结果表明，对于慢性肾衰竭血液透析患者，奈达铂 - 依托泊苷联合化疗可能比含顺铂的方案更安全，并且有望获得令人满意的疗效。
Zotero 插件